Mechanisms of Diabetic Kidney Disease in American Indians
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01878045|
Recruitment Status : Enrolling by invitation
First Posted : June 14, 2013
Last Update Posted : April 12, 2018
- An ongoing study is looking at American Indians who have kidney problems caused by type 2 diabetes. Kidney disease due to type 2 diabetes is a major problem in American Indians. We previously found that early treatment of kidney disease with losartan was probably beneficial for reducing progression of the disease. Researchers now want to see if these benefits continue to be seen several years after the end of the treatment study.
- To study long-term benefit of losartan treatment for diabetic kidney disease in American Indians with type 2 diabetes.
- Participants in the American Indian diabetic kidney disease study (OH95-DK-N037).
- Participants will have a physical exam and medical history before starting the study. Blood and urine samples will be collected.
- Participants will have a set of tests as part of this study. Those who have severe kidney problems, such as kidney failure, will only have a basic kidney exam with scans. The remaining participants will have a full urine collection and analysis. They will also provide a kidney biopsy.
- Treatment will not be provided as part of this study.
|Condition or disease|
|Nervous System Diabetic Kidney Disease Diabetes Mellitus, Type 2|
|Study Type :||Observational|
|Actual Enrollment :||134 participants|
|Official Title:||Determinants of Diabetic Nephropathy in American Indians|
|Study Start Date :||June 12, 2013|
|Estimated Primary Completion Date :||December 31, 2022|
|Estimated Study Completion Date :||January 25, 2035|
- End-Stage Renal Disease [ Time Frame: On-going ]
- Diabetic Neuropathy [ Time Frame: On-going ]
- Diabetic Retinopathy [ Time Frame: On-going ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01878045
|United States, Arizona|
|Phoenix, Arizona, United States, 85014|
|Principal Investigator:||Robert G Nelson, M.D.||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|